These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 15870223

  • 1. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK, Devlin L, Taal MW, Fluck RJ, McIntyre CW.
    Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
    [Abstract] [Full Text] [Related]

  • 2. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.
    J Nephrol; 2001 Aug; 14(3):176-83. PubMed ID: 11439741
    [Abstract] [Full Text] [Related]

  • 3. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J, Piecha G, Kokot F, Wiecek A.
    J Nephrol; 2003 Aug; 16(5):710-5. PubMed ID: 14733418
    [Abstract] [Full Text] [Related]

  • 4. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
    Izumi M, Shirai K, Ito K, Miyamoto T, Matsumoto A, Takenaka Y, Nakagawa K, Yamanashi T, Takamitsu Y, Nakanish T.
    Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM.
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [Abstract] [Full Text] [Related]

  • 6. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
    Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM.
    Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM.
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriu A.
    Nephron Clin Pract; 2004 Apr; 97(1):c17-22. PubMed ID: 15153763
    [Abstract] [Full Text] [Related]

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 10. Calcium exposure and removal in chronic hemodialysis patients.
    Sigrist M, McIntyre CW.
    J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 12. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T, Fujii N, Ito T, Imai E.
    Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
    [Abstract] [Full Text] [Related]

  • 13. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM.
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [Abstract] [Full Text] [Related]

  • 14. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 May; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 15. Determinants of progressive vascular calcification in haemodialysis patients.
    Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK.
    Nephrol Dial Transplant; 2004 Jun; 19(6):1489-96. PubMed ID: 15102961
    [Abstract] [Full Text] [Related]

  • 16. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
    Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, Sato Y, Hara S, Eto T.
    Ren Fail; 2005 Jun; 27(4):361-5. PubMed ID: 16060120
    [Abstract] [Full Text] [Related]

  • 17. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB, Fatma LB, Barbouch S, Kaaroud H, Helal I, Hedri H, Abdallah TB, Maiz HB, Kheder A.
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [Abstract] [Full Text] [Related]

  • 18. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G, Cardinal H, Mailhot M, Ste-Marie LG, Roy L.
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [Abstract] [Full Text] [Related]

  • 19. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.
    Spasovski G, Gelev S, Masin-Spasovska J, Selim G, Sikole A, Vanholder R.
    Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363
    [Abstract] [Full Text] [Related]

  • 20. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
    Gallar P, Ortega O, Gutiérrez M, Muñoz M, Hilara L, Oliet A, Rodríguez I, Giménez E, Vigil A.
    Nefrologia; 2000 Oct; 20(4):355-61. PubMed ID: 11039261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.